THERAPEUTIC SUBSTITUTION POST-PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS-Reference-Cited by-同舟云学术

THERAPEUTIC SUBSTITUTION POST-PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS

Published:2013-05-21 Issue:5 Volume:23 Page:621-630
ISSN:1057-9230
Container-title:Health Economics
language:en
Short-container-title:Health Econ.

Author:

Vandoros Sotiris¹

Affiliation:

1. London School of Economics and Political Science; London UK

Publisher

Wiley

Subject

Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hec.2935/fullpdf

Reference55 articles.

1. Prescription drug spending trends in the United States: looking beyond the turning point;Aitken;Health Affairs,2009

2. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer;Beker;European Journal of Gastroenterology and Hepatology,1995

3. Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-hatch legislation;Berndt;International Journal of the Economics of Business,2011

4. Pharmaceutical innovations and market dynamics: tracking effects on price indexes for antidepressant drugs;Berndt;Brookings Papers on Economic Activity: Microeconomics,1996

5. Caves RE Whinston MD Hurwitz MA 1991 Patent expiration, entry and competition in the U.S. pharmaceutical industry: an exploratory analysis Brookings Studies on Economic Activity

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation;PLOS ONE;2024-05-02

2. Therapeutic Substitution in Response to Patent Expiry? Statins in Australia*;Economic Papers: A journal of applied economics and policy;2023-12-09

3. The role of patient organisations in research and development: Evidence from rare diseases;Social Science & Medicine;2023-12

4. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period;International Journal of Cardiology;2023-01

5. Deregulation on branded and generic drugs price and its effect: a study of Chinese pharmaceutical market;International Journal of Health Governance;2022-11-22